October 12, 2018 08:56 AM EDT

Bristol-Myers concedes a PhIII lung cancer flop for Opdivo as competition heats up in SCLC

Bristol-Myers Squibb $BMY has run into another dead end in exploring the lung cancer market.

The big biotech reported that its Phase III …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bris­tol-My­ers con­cedes a PhI­II lung can­cer flop for Op­di­vo as com­pe­ti­tion heats up in SCLC